Clinical trials: 5-Fluorouracil
Colorectal Cancer
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer that has recurred after previous treatment and that cannot be safely removed by surgery or has spread…
- Trial name
- NCT07775287
- Testing
- Petosemtamab, Cetuximab, Bevacizumab
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 600 people
- Sponsor
- Genmab
Pancreatic Cancer
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous SoC chemotherapy.
- Trial name
- NCT03329248
- Testing
- ALT-803, ETBX-011, GI-4000
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- ImmunityBio, Inc.
Biliary Tract Cancer
XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors
The main purpose of this study is to determine if XL119 is more effective than the combination of 5-fluorouracil (5FU) and leucovorin (LV) in prolonging the survival of subjects with advanced biliary tumors.
- Trial name
- NCT00090025
- Testing
- becatecarin, 5-Fluorouracil Plus Leucovorin
- Where
- 59 sites in United States, Belgium and 9 more
- Volunteers
- 248 people
- Sponsor
- Helsinn Healthcare SA
Urinary Bladder Neoplasms
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Researchers are looking for new ways to treat muscle-invasive bladder cancer (MIBC). MIBC is a type of cancer that has not spread from the muscles in the bladder to other parts of the body.
- Trial name
- NCT04241185
- Testing
- Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes)
- Where
- 134 sites in United States, Australia and 23 more
- Volunteers
- 520 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Cancer
A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer
This is a Phase 3, multicenter, randomized, double-blind, placebo controlled study of Rilotumumab (AMG 102) with Cisplatin and Capecitabine (CX) for untreated advanced mesenchymal epithelial transition factor (MET)-positive…
- Trial name
- RILOMET-2 (NCT02137343)
- Testing
- Rilotumumab, Cisplatin, Capecitabine
- Where
- 25 sites in Japan, South Korea
- Volunteers
- 34 people
- Sponsor
- Amgen
Unresectable/Metastatic Colorectal Cancer
EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer
This is an open-label, multicenter, Phase Ib trial designed to evaluate the safety, tolerability, and preliminary efficacy of EMB-01 in combination with chemotherapy in patients with unresectable or metastatic colorectal cancer…
- Trial name
- NCT07649655
- Testing
- EMB-01, Irinotecan, TAS-102
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Neoplasms
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology.
- Trial name
- NCT02723955
- Testing
- feladilimab (GSK3359609), GSK3174998, Pembrolizumab
- Where
- 28 sites in United States, Australia and 7 more
- Volunteers
- 829 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
This study will compare DS 8201a to standard treatment. Participants must have HER2 breast cancer that has been treated before. Their cancer: cannot be removed by an operation has spread to other parts of the body
- Trial name
- NCT03523585
- Testing
- Trastuzumab deruxtecan, Capecitabine, Lapatinib
- Where
- 227 sites in United States, Australia and 13 more
- Volunteers
- 608 people
- Sponsor
- Daiichi Sankyo
Metastatic Colorectal Cancer
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and tolerability of BAX69 in combination with 5-fluorouracil (5-FU)/leucovorin (LV) or panitumumab to determine the recommended phase II dose (RP2D) of each combination; and to…
- Trial name
- NCT02448810
- Testing
- BAX69 + infusional 5-FU/LV, BAX69 + panitumumab, BAX69 + 5-FU/LV
- Where
- 12 sites in United States
- Volunteers
- 115 people
- Sponsor
- Baxalta now part of Shire
Cancer of the Head and Neck, Neoplasms, Head and Neck
Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer
To evaluate the objective response rate of oxaliplatin combined with 5-FU in patients with recurrent or metastatic head and neck cancer and to assess the safety profile of these treatment regimen.
- Trial name
- NCT01370876
- Testing
- Oxaliplatin
- Where
- Taiwan
- Volunteers
- 46 people
- Sponsor
- Nang Kuang Pharmaceutical Co., Ltd.
Locally Advanced Esophageal or GE Junction Cancer
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
This is a Phase 1/ 2, open-label, single-center study of preoperative chemoradiotherapy and AT-101 in patients with locally advanced esophageal or gastroesophageal junction cancer.
- Trial name
- NCT00561197
- Testing
- AT-101
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ascenta Therapeutics
Colorectal Cancer
An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer
The purpose of this study is to investigate biomarkers which may be predictors of efficacy and safety of treatment with mFOLFOX6 + bevacizumab versus mFOLFOX6 + panitumumab therapy in patients with chemotherapy-naïve unresectable…
- Trial name
- NCT02394834
- Testing
- oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
- Where
- 151 sites in Japan
- Volunteers
- 757 people
- Sponsor
- Takeda
Colorectal Cancer
A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin
This open-label single arm study will evaluate the efficacy and safety of Avastin added to XELOX or FOLFOX in patients with metastatic colorectal cancer and disease progression on 1st line therapy with FOLFIRI plus Avastin.
- Trial name
- NCT01077739
- Testing
- fluorouracil (5FU), leucovorin, bevacizumab [Avastin]
- Where
- 28 sites in Belgium
- Volunteers
- 75 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer, Lung Cancer
Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
This is a Phase I, multi-center study of GM-CT-01, which has been shown to increase the anti-tumor activity of 5-fluorouracil in mice.
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Head and Neck Cancer
- Trial name
- NCT00054977
- Testing
- GM-CT-01, 5-fluorouracil
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Galectin Therapeutics Inc.
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.
Gastric Cancer, Gastroesophageal Junction Cancer
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
This is a Phase 2/3, randomized, open-label study for the treatment of patients with HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer conducted in two parts.
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
- Trial name
- MAHOGANY (NCT04082364)
- Testing
- margetuximab, Retifanlimab, Tebotelimab
- Where
- 73 sites in United States, China and 7 more
- Volunteers
- 82 people
- Sponsor
- MacroGenics
Solid Tumor
A Study in Advanced Solid Tumors
The primary purpose of this study is to help answer the following research question(s): To see how the body absorbs, processes, and gets rid of cetuximab when the drug is taken in combination with carboplatin [pharmacokinetic…
- Trial name
- NCT01063075
- Testing
- Cetuximab, Carboplatin, 5 - FU
- Where
- 8 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Eli Lilly and Company
Advanced Cancer
A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer
This is a Phase 1 study during which patients with advanced/metastatic solid tumors will receive investigational study drug ARRY-334543 and capecitabine.
- Trial name
- NCT00710736
- Testing
- ARRY-334543, EGFR/ErbB2 inhibitor; oral, Capecitabine, 5-fluorouracil prodrug; oral
- Where
- 4 sites in United States, Canada
- Volunteers
- 29 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Unresectable or Metastatic Colorectal Cancer
Study Of Sunitinib With FOLFIRI In Colorectal Cancer
To evaluate the efficacy, safety and pharmacokinetics of sunitinib plus FOLFIRI (irinotecan, 5-FU and l-leucovorin) in the first-line treatment of Japanese mCRC patients
- Trial name
- NCT00668863
- Testing
- FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil), Sunitinib
- Where
- 10 sites in Japan
- Volunteers
- 71 people
- Sponsor
- Pfizer
Gastrointestinal Cancer, Metastatic
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
This study is open to adults with advanced colorectal cancer or with advanced pancreatic cancer. The study has 2 parts. In the first part, participants with colorectal cancer get a medicine called BI 905711 combined with…
- Trial name
- NCT05087992
- Testing
- BI 905711, FOLFIRI, Bevacizumab
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 13 people
- Sponsor
- Boehringer Ingelheim